Retatrutide, a triple-hormone receptor agonist of GIP, GLP-1, and glucagon receptors, demonstrated clinically meaningful improvements in HbA1c and significant body weight reductions in adults with type 2 diabetes in a Phase 2 study comparing eating behaviors, presented at the American Diabetes Association Scientific Sessions in Orlando, Florida.
In the double-blind, double-dummy study, adults with type 2 diabetes were randomized to receive subcutaneous placebo once weekly, dulaglutide (DU) 1.5 mg once weekly, or Retatrutide (RETA) 0.5, 4, 8, or 12 mg once weekly for 36 weeks. Eating behavior was assessed at baseline and week 36 using the 51-item Three-Factor Eating Questionnaire, comprising cognitive restraint of eating, disinhibition, and perceived hunger.
Overall, 281 adults with a mean baseline age of 56 years, a mean type 2 diabetes duration of 8.1 years, mean HbA1c of 8.3%, and mean BMI of 35.0 kg/m² were randomized. At week 36, adults treated with RETA 8 mg and 12 mg showed significantly reduced eating inventory disinhibition and perceived hunger scores compared to placebo. Those treated with RETA 12 mg also had significantly reduced disinhibition and perceived hunger scores compared to DU, and a significantly reduced cognitive restraint of eating score compared to placebo.
Specifically, the changes from baseline in cognitive restraint of eating, disinhibition, and perceived hunger domain scores at 36 weeks found the highest dose of RETA (12 mg) resulted in a 2.7% reduction in disinhibition and a 2.4% reduction in perceived hunger, both statistically significant when compared to placebo and DU.
A full list of disclosures can be found in the published research.